Table 2.

Margetuximab adverse events reported in ≥9  (>15%) patients overall regardless of causality and Grade ≥3 margetuximab-related adverse events reported, by MedDRA preferred term

	Regimen A, N = 34		Regimen B, N = 32		Total, N = 66
	Grade		Grade		Grade
	Any n  (%)	≥3 n  (%)	Any n  (%)	≥3 n  (%)	Any n  (%)	≥3 n  (%)
Fatigue	8  (24)	0	7  (22)	0	15  (23)	0
Pyrexia	10  (29)	0	4  (13)	0	14  (21)	0
Anemia	8  (24)	0	5  (16)	0	13  (20)	0
Nausea	10  (29)	0	3  (9)	0	13  (20)	0
Infusion-related reaction	5  (15)	1  (3)	7  (22)	0	12  (18)	1  (2)
Upper respiratory infection	3  (9)	0	9  (28)	0	12  (18)	0
Vomiting	8  (24)	0	4  (13)	0	12  (18)	0
Decreased appetite	8  (24)	0	3  (9)	0	11  (17)	0
Diarrhea	4  (12)	0	7  (22)	0	11  (17)	0
Lymphopenia	2  (6)	0	9  (28)	0	11  (17)	0
Headache	3  (9)	0	7  (22)	0	10  (15)	0
Lymphocyte count decreased	5  (15)	2  (6)	3  (9)	0	8  (12)	2  (3)
Lipase increased	3  (9)	0	5  (16)	1  (3)	8  (12)	1  (2)
Blood amylase increased	2  (6)	0	5  (16)	2  (6)	7  (11)	2  (3)
Blood alkaline phosphatase increased	2  (6)	1  (3)	5  (16)	0	7  (11)	1  (2)